Tvardi Therapeutics
A clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases.
Employees
Enterprise value
$296—444m
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
National Institutes of Health(exited)
V Foundation(exited)
ArrowMark Partners(exited)
Sporos Bioventures(exited)
Slate Path Capital(exited)
Palkon Capital(exited)
683 Capital(exited)
Cavendish Impact Capital(exited)
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.